Skip to main content

Table 2 Pharmacotherapy

From: Impact of protocolized diuresis for de-resuscitation in the intensive care unit

Parameter

Historical cohort (n = 273)

Intervention cohort (n = 91)

p value

Furosemide dosing

 Starting dose (mg) a

40 (20–40)

40 (40–40)

0.003

 Day one total daily dose (mg) a

40 (40–60)

80 (40–120)

< 0.0001

 Day two total daily dose (mg)a

0 (0–40)

80 (20–120)

< 0.0001

 Day three total daily dose (mg) a

0 (0–20)

0 (0–80)

0.0007

 Total cumulative dose (mg)a

80 (40–200)

240 (120–420)

< 0.0001

 Conversion to continuous infusion b

32 (11.7)

8 (8.8)

0.562

 First to last dose furosemide (days) a

4.9 (1.4–12.4)

4.8 (3.1–9.8)

0.165

Diuresis adjuncts

 Metolazoneb

15 (5.5)

30 (32.9)

< 0.0001

 Chlorothiazidec

48 (17.6)

6 (6.6)

0.402

 Acetazolamideb

14 (5.1)

14 (15.4)

0.001

 Albuminc

29 (10.6)

2 (2.2)

0.009

 Day one potassium supplementationa

40 (40–60)

60 (40–80)

0.007

 Day two potassium supplementationa

40 (40–60)

60 (40–100)

0.002

 Day three potassium supplementationa

50 (40–80)

70 (60–100)

0.002

Other medication exposure

 Total nephrotoxin exposurea

1 (1–2)

1 (1–2)

0.288

 Aminoglycosideb

27 (9.9)

8 (8.8)

0.758

 Beta-lactamb

227 (83.2)

75 (92.4)

0.872

 Intravenous antiviralb

11 (4.0)

12 (13.2)

0.002

 ACE inhibitor and/or ARBb

49 (17.9)

13 (14.3)

0.421

 Amphotericin Bc

5 (1.8)

3 (3.3)

0.418

 Intravenous sulfamethoxazole-trimethoprimc

19 (6.9)

4 (7.7)

0.465

 Intravenous vancomycinb

153 (56.0)

51 (56.0)

1.000

 Combination vancomycin and piperacillin-tazobactamb

88 (32.2)

30 (32.9)

0.897

  1. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
  2. aWilcoxon rank sum, median (interquartile range)
  3. bChi-square test; number (percentage)
  4. cFisher’s exact, number (percentage)